Pfizer FY2026 EPS Estimate Increased by Erste Group Bank

Pfizer Inc. (NYSE:PFE) – Equities research analysts at Erste Group Bank raised their FY2026 earnings per share (EPS) estimates for shares of Pfizer in a research note issued on Wednesday, February 18th. Erste Group Bank analyst H. Engel now expects that the biopharmaceutical company will post earnings of $2.97 per share for the year, up from their prior estimate of $2.96. The consensus estimate for Pfizer’s current full-year earnings is $2.95 per share. Erste Group Bank also issued estimates for Pfizer’s FY2027 earnings at $2.84 EPS.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a return on equity of 20.25% and a net margin of 12.42%.The business had revenue of $17.56 billion during the quarter, compared to analyst estimates of $16.93 billion. During the same quarter in the previous year, the firm earned $0.63 EPS. The company’s quarterly revenue was down 1.2% compared to the same quarter last year.

Several other research analysts also recently commented on PFE. Cantor Fitzgerald reissued a “neutral” rating and issued a $27.00 price target on shares of Pfizer in a report on Wednesday, February 4th. Morgan Stanley dropped their price objective on Pfizer from $32.00 to $28.00 and set an “equal weight” rating for the company in a research note on Friday, December 12th. Daiwa Securities Group lowered Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 target price on the stock. in a research note on Thursday, February 12th. Bank of America dropped their price target on Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a research report on Monday, December 15th. Finally, Wolfe Research set a $24.00 price objective on Pfizer and gave the stock an “underperform” rating in a report on Wednesday, December 17th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, thirteen have given a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Pfizer presently has an average rating of “Hold” and a consensus target price of $27.84.

Pfizer Price Performance

Shares of NYSE:PFE opened at $26.66 on Monday. The company has a 50 day moving average of $25.95 and a 200 day moving average of $25.32. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62. The stock has a market cap of $151.55 billion, a P/E ratio of 19.60 and a beta of 0.47. Pfizer has a 12 month low of $20.92 and a 12 month high of $27.94.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, January 23rd. This represents a $1.72 annualized dividend and a dividend yield of 6.5%. Pfizer’s dividend payout ratio (DPR) is 126.47%.

Institutional Investors Weigh In On Pfizer

A number of institutional investors have recently made changes to their positions in PFE. Brighton Jones LLC grew its holdings in shares of Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after purchasing an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC raised its holdings in Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after buying an additional 2,087 shares during the last quarter. United Bank boosted its position in Pfizer by 12.4% during the 2nd quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock valued at $1,408,000 after buying an additional 6,415 shares during the period. Sage Mountain Advisors LLC grew its holdings in Pfizer by 47.3% in the 2nd quarter. Sage Mountain Advisors LLC now owns 22,789 shares of the biopharmaceutical company’s stock worth $552,000 after acquiring an additional 7,322 shares during the last quarter. Finally, Curio Wealth LLC increased its position in shares of Pfizer by 36,600.0% in the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 1,098 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.